EYLEA (Non-English)
$1,499.00
| Quantity | Discount (%) | Price |
|---|---|---|
| 1 - 5 | — | $1,499.00 |
| 6 - 10 | 6.67 % | $1,399.00 |
| 11 - 20 | 7.34 % | $1,389.00 |
| 21+ | 8.01 % | $1,379.00 |
EYLEA® (aflibercept) is a recombinant fusion protein formulated as an intravitreal injection to treat various retinal diseases caused by abnormal blood vessel growth and vascular leakage in the eye. It acts as a VEGF inhibitor, specifically binding to VEGF-A, VEGF-B, and placental growth factor (PlGF), preventing these from interacting with their native receptors. This action helps reduce retinal edema, neovascularization, and vision loss. EYLEA® is commonly indicated for patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema after retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP). The product is administered under strict aseptic conditions by a trained ophthalmologist.


